Apolipoproteins as markers and managers of coronary risk

Area of Science:

• Cardiovascular Medicine
• Clinical Biochemistry
• Epidemiology

Background:

• Coronary artery disease (CAD) is a leading cause of death globally.
• Current lipid profiles, including LDL cholesterol, have limitations in predicting CAD risk.
• Effective risk assessment and therapeutic targets are crucial for managing CAD.

Purpose of the Study:

• To evaluate apolipoprotein B-100 (apoB) as a superior predictor of coronary events compared to LDL cholesterol.
• To assess the utility of apolipoproteins (apoB and apoA-I) in routine cardiovascular risk assessment.
• To determine if apolipoproteins can serve as therapeutic targets for dyslipidemias.

Main Methods:

• Analysis of epidemiological studies and statin trial data.
• Comparison of predictive values of apoB, apoA-I, LDL cholesterol, and non-HDL cholesterol.
• Evaluation of standardization, automation, cost-effectiveness, and precision of apolipoprotein measurements.

Main Results:

• Apolipoprotein B-100 (apoB), with or without apoA-I, demonstrates superior prediction of coronary events over LDL cholesterol.
• Apolipoprotein measurements are standardized, automated, cost-effective, convenient, and precise.
• ApoB may be preferable to non-HDL cholesterol for risk assessment.
• ApoB measurement is particularly relevant for dyslipidemias with elevated triglycerides.

Conclusions:

• Routine measurement of apoB and potentially apoA-I should be added to the standard lipid profile.
• Apolipoproteins, especially apoB, can improve the assessment of atherogenic potential in lipid disorders.
• ApoB could potentially replace the standard lipid profile as a therapeutic target in high-risk patients.